We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi acquired Tidal Therapeutics, a preclinical stage biotech company with a novel mRNA-platform for reprogramming of immune cells, for $160 million upfront and up to $310 million in milestones.